Institution
Moorfields Eye Hospital
Healthcare•London, United Kingdom•
About: Moorfields Eye Hospital is a healthcare organization based out in London, United Kingdom. It is known for research contribution in the topics: Visual acuity & Glaucoma. The organization has 3721 authors who have published 6790 publications receiving 246004 citations.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A single onabotulinumtoxinA treatment with doses≥100 U resulted in statistically significant and clinically meaningful improvement in HRQOL by week 2 compared with placebo, and this improvement was sustained for ≤36 wk in patients with idiopathic OAB and UUI who were inadequately managed by oral antimuscarinics.
73 citations
••
TL;DR: Ranibizumab therapy in the treatment of diabetic macular edema seems to improve retinal function and structure as demonstrated by this evaluation of different assessment methods.
73 citations
••
TL;DR: The management of acute occlusion of the central retinal artery has not changed over the past 30 years, although the potential benefits of superselective intra-arterial fibrinolytic therapy warrant evaluation in a randomised controlled trial.
Abstract: Purpose/Background—Central retinal artery occlusion (CRAO) is usually a blinding event, and is not an infrequent presentation to the accident and emergency (A&E) department. The evidence-base in support of current treatment options is weak.
Methods—This paper reviewed the literature germane to the diagnostic, therapeutic and prognostic aspects of retinal arterial occlusive disease.
Results—The visual prognosis associated with CRAO remains poor, and current therapeutic practices are of unproven benefit. The non-ophthalmologist in the A&E department should lie the patient flat and give a stat dose of intravenous acetazolamide in an attempt to improve the retinal perfusion pressure.
Conclusion—The management of acute occlusion of the central retinal artery has not changed over the past 30 years, although the potential benefits of superselective intra-arterial fibrinolytic therapy warrant evaluation in a randomised controlled trial. The identification of underlying pathology is an essential component of medical care, and all cases should be followed up by an ophthalmologist because of the possibility of ocular rubeosis.
73 citations
••
TL;DR: In a northern region of Tanzania, diabetes is an under-recognized health condition, despite the fact that many people either have diabetes or are at increased risk for developing diabetes, and the prevalence of diabetes-associated complications was high.
Abstract: Background In sub-Saharan Africa, diabetes is a growing burden, yet little is known about its prevalence, risk factors, and complications. To address these gaps and help inform public health efforts aimed at prevention and treatment, we conducted a community-based study assessing diabetes epidemiology. Methods and Findings We conducted a stratified, cluster-designed, serial cross-sectional household study from 2014–2015 in the Kilimanjaro Region, Tanzania. We used a three-stage cluster probability sampling method to randomly select individuals. To estimate prevalence, we screened individuals for glucose impairment, including diabetes, using hemoglobin A1C. We also screened for hypertension and obesity, and to assess for potential complications, individuals with diabetes were assessed for retinopathy, neuropathy, and nephropathy. We enrolled 481 adults from 346 urban and rural households. The prevalence of glucose impairment was 21.7% (95% CI 15.2–29.8), which included diabetes (5.7%; 95% CI 3.37–9.47) and glucose impairment with increased risk for diabetes (16.0%; 95% CI 10.2–24.0). Overweight or obesity status had an independent prevalence risk ratio for glucose impairment (2.16; 95% CI 1.39–3.36). Diabetes awareness was low (35.6%), and few individuals with diabetes were receiving biomedical treatment (33.3%). Diabetes-associated complications were common (50.2%; 95% CI 33.7–66.7), including renal (12.0%; 95% CI 4.7–27.3), ophthalmic (49.6%; 95% CI 28.6–70.7), and neurological (28.8%; 95% CI 8.0–65.1) abnormalities. Conclusions In a northern region of Tanzania, diabetes is an under-recognized health condition, despite the fact that many people either have diabetes or are at increased risk for developing diabetes. Most individuals were undiagnosed or untreated, and the prevalence of diabetes-associated complications was high. Public health efforts in this region will need to focus on reducing modifiable risk factors, which appear to include obesity, as well as early detection that includes increasing awareness. These findings highlight a growing urgency of diabetes prevention in this region as well as the need for treatment, including management of complications.
73 citations
••
TL;DR: There was no evidence of worsening macular ischemia in either group in a prospective randomized, single-center 2-year trial comparing intravitreal bevacizumab and laser therapy in patients with diabetic macular edema.
Abstract: Purpose: The purpose of this study was to assess macular perfusion with fundus fluorescein angiography at the 4-month time point in a prospective randomized, single-center 2-year trial comparing intravitreal bevacizumab and laser therapy in patients with diabetic macular edema.Methods: All enrolled patients had standard Early Treatment of Diabetic Retinopathy Study 7-field fundus photographs and fundus fluorescein angiography at baseline and subsequently at 4-month intervals. Patients were excluded from the study if either the greatest linear dimension of the foveal avascular zone (FAZ) was >1,000 mu m in diameter or there was severe perifoveal capillary loss (Early Treatment of Diabetic Retinopathy Study criteria) on fundus fluorescein angiography. The fundus fluorescein angiograms of the bevacizumab (n = 42) and laser (n = 38) groups were graded for greatest linear dimension of the FAZ, area of the FAZ, and perifoveal capillary loss by the Moorfields Reading Centre in a masked fashion.Results: At baseline, the mean greatest linear dimension of the FAZ in the laser group was 685 +/- 262 mu m and in the bevacizumab group was 737 +/- 262 mu m. There was no significant difference at the 4-month time point (P = 0.40) with the mean greatest linear dimension of the FAZ in the laser group recorded as 678 +/- 221 mu m and in the bevacizumab group was 678 +/- 231 mu m. At baseline, the median area of the FAZ in the laser group was 0.36 mm(2) (interquartile range, 0.21-0.46) and in the bevacizumab group was 0.33 mm(2) (interquartile range, 0.27-0.49). There was no significant difference at the 4-month time point (P = 0.30) with the median area of the FAZ in the laser group recorded as 0.35 mm(2) (interquartile range, 0.20-0.52) and in the bevacizumab group was 0.34 mm(2) (interquartile range, 0.23-0.47). Similarly, there was no difference between the two treatment groups (P = 0.64) when a comparison was made of the number of grades of change in perifoveal capillary loss observed in each patient. To date, no patients have been withdrawn from the study because of worsening macular ischemia.Conclusion: At 4 months, there was no evidence of worsening macular ischemia in either group. RETINA 30:781-786, 2010
73 citations
Authors
Showing all 3754 results
Name | H-index | Papers | Citations |
---|---|---|---|
Rakesh K. Jain | 200 | 1467 | 177727 |
David Baker | 173 | 1226 | 109377 |
Nilesh J. Samani | 149 | 779 | 113545 |
Paul Mitchell | 146 | 1378 | 95659 |
Andrew J. Lees | 140 | 877 | 91605 |
Nick C. Fox | 139 | 748 | 93036 |
Alan J. Thompson | 131 | 718 | 82324 |
Martin N. Rossor | 128 | 670 | 95743 |
Nicholas W. Wood | 123 | 614 | 66270 |
Peter J. Goadsby | 123 | 946 | 73783 |
James A. Wells | 112 | 462 | 50847 |
Simon Cousens | 102 | 361 | 54579 |
Kailash P. Bhatia | 102 | 892 | 44372 |
Stafford L. Lightman | 98 | 714 | 36735 |
Simon Shorvon | 98 | 485 | 30672 |